We are excited to announce that ViewMind Inc. will present new results to identify frontotemporal dementia in the MCI stage (prodromal FTD) and to differentiate against Alzheimer’s disease in the MCI stage (prodromal AD).
Patients were tracked in a 4-year prospective study until the underlying causality of MCI was clinically diagnosed.
This is based on ViewMind Inc.’s Atlas cognitive biomarker – using ocular digital phenotyping technology. Results will be presented on Sunday, July 16th, in Amsterdam at the Alzheimer’s Association® International Conference (AAIC2023).
Related Posts
R3i Ventures, provider of successful start-ups
R3i Ventures, provider of successful start-ups Homepage >> News >> R3i Ventures, provider of successful start-ups Click to read the news Related Posts
Learn About Developments in Precision Diagnostics on Advancements TV Series
Learn About Developments in Precision Diagnostics on Advancements TV Series Homepage >> News >>Learn About Developments in Precision Diagnostics on Advancements TV Series Developments in Precision Diagnostics on
ViewMind- Getting Ahead of Alzheimer’s with AI
ViewMind- Getting Ahead of Alzheimer’s with AI Homepage >> News >> ViewMind- Getting Ahead of Alzheimer’s with AI Click to read the news Related Posts
